This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Stemon Inc.


STEMON is looking for Series B investment and Global partnerships. STEMON is a biomedical company that develops digital induction of cell therapies such as stem cells and customized exosomes using Entr technology. Entr is gene free of cellular reprogramming method and a short word of ultrasound-directed permeation of Environmental transition-guided cellular reprogramming. Besides, Entr technology using various environmental composition (conditioned cell culture media) induces various reprogramming factors in the exosomes (reprosome) suitable for environmental characteristics. Entr technology overcomes problems of conventional cell therapy of stem cells and exosomes, low efficiency and safety. Recently, our company developed an automatic equipment, UltraRepro, that can implement Entr technology digitally. UltraRepro will open an era where individual cell therapy can be performed in future homes, as seen science fiction movies.